Kedrion bpl. As the historic facility of BPL, it has been continuously adapted ove...

Kedrion bpl. As the historic facility of BPL, it has been continuously adapted over the years to keep pace with the plasma-derived industry. Nov 4, 2025 · Kedrion Biopharma Kedrion Biopharma is a private Italian company specializing in plasma-derived medicinal products, making it a very direct competitor to Kamada. The plant, spanning 130,000 square meters, is fully Sep 1, 2022 · Kedrion Biopharma (“Kedrion”) and Bio Products Laboratory (“BPL”) are two leading bio pharmaceutical companies that develop, manufacture and commercialize therapeutic products from blood plasma The Permira Funds have partnered with the Marcucci family to combine two highly complementary companies, BPL and Kedrion, creating an industry leader in plasma derivatives and rare disease Sep 10, 2025 · Kedrion’s plasma-derived therapies help people suffering from debilitating conditions like Hemophilia and Immune Deficiencies. Ugo Di Francesco, currently CEO of Chiesi Group, has been appointed the new CEO of the combined company, effective January 2023. 25 The combination of BPL and Kedrion creates a global player for medicinal products derived from human blood plasma, which treat patients with rare and life-threatening conditions. Recently, Kedrion merged with Bio Products Laboratory (BPL), a UK-based competitor, and is backed by the private equity firm Permira. Mar 6, 2026 · Kedrion’s plasma-derived therapies help people suffering from debilitating conditions like Hemophilia and Immune Deficiencies. Global private equity major Permira has completed the joint acquisition and combination of Kedrion and BPL, creating a major player for medicinal products derived from human blood plasma. Mar 6, 2026 · Major global companies in the Plasma Collection and Processing market include CSL Behring, Baxter, Grifols, Octapharma, Takeda, Octaphaarma, Kedrion, BPL and LFB Group, among others. The Elstree production site is located 25 km north of London, UK. rgustkh bwdjc rgxig fmdoz itveo qtysn opyeg egksdy ygtqny lvi